In the making: blood test for Alzheimer’s disease

March 25, 2009 by  
Filed under ALZHEIMER'S

1 Star2 Stars3 Stars4 Stars5 Stars (No Ratings Yet)

Diagnosing Alzheimer’s disease is often a problematic process. Over the blood-test1years, the field of biotechnology has tried to come up with screening and testing methods that can help identify this disease. While diagnostic biomarkers for many diseases can be identified in a blood sample, this has so far proved elusive for Alzheimer’s. However, there is a lot of promise in biomarkers found in the cerebrospinal fluid (CSF), which makes a lot of sense – considering the CSF’s proximity to the brain. CSF is a colorless liquid found in the central nervous system (brain and spinal cord).

Taking CSF samples however is a bit controversial since it entails a procedure called a lumbar puncture or spinal tap, which is basically done inserting a needle in the lower part of the spine to collect the fluid. A spinal tap is performed to diagnose diseases affecting the nervous system.

Many experts feel that a lumbar puncture can be painful and presents some risks, complicated by the type of patients – elderly and disoriented – one is dealing with. Others claim that a lumbar puncture is essentially safe and straightforward. This controversy in relation to the CSF has led many researchers to explore further the possible of developing a blood test for Alzheimer’s.

And it seems that their efforts are bearing fruit.

American researchers “have revealed a direct relationship between two specific antibodies and the severity of Alzheimer’s disease symptoms, raising hopes that a diagnostic blood test for the devastating disorder is within reach.”

The researchers focused on antibodies that the body produces in response to two Alzheimer-associated proteins. One of these proteins is the well-known amyloid-beta which is responsible for the formation of plaques in the brains of Alzheimer’s patients. The other protein is the less known RAGE which is involved in the normal human aging process. However, it has been observed the RAGE is expressed at higher levels in the brains of people with Alzheimer’s.

The researchers found that anti-amyloid beta and anti-RAGE antibodies are significantly higher in the group with Alzheimer’s compared to a control group without Alzheimer’s. Furthermore, the concentrations of the two antibodies in the blood seem to be significantly associated with the severity of the disease.

According researcher Shyamala Mruthint

“Alzheimer’s is an inflammatory disease of the brain, and these two antibodies give us a way to measure that inflammation. Using them as an early diagnostic marker may allow us to start drug treatment early, when it’s most effective, to increase the patient’s quality of life.”

Related Posts with Thumbnails
Print Friendly, PDF & Email
  • Winsor Pilates


4 Responses to “In the making: blood test for Alzheimer’s disease”
  1. That would definitely ease the way of life for people but all the test should be double checked with doctors.

  2. Banxietyy07 says:

    that is good news.a blood test for detecting alzheimers disease.

  3. Raquel says:

    Thanks for the comment, Kevin. We definitely recommend the same thing here at Battling for Health.

  4. As a physician, I would strongly recommend visiting a healthcare provider before taking any drug.

Speak Your Mind

Tell us what you're thinking...
and oh, if you want a pic to show with your comment, go get a gravatar!


Random Battling For Health Products From Our Store

NOTE: The contents in this blog are for informational purposes only, and should not be construed as medical advice, diagnosis, treatment or a substitute for professional care. Always seek the advice of your physician or other qualified health professional before making changes to any existing treatment or program. Some of the information presented in this blog may already be out of date.

Read previous post:
Short sleep increases diabetes risk

Daylight savings time has started in the US. In Europe, we are only springing forward come end of March. In...